Recce Pharmaceuticals (ASX:RCE) Interest Expense: A$-1.30 Mil (TTM As of Dec. 2025)

What is Recce Pharmaceuticals Interest Expense?

Recce Pharmaceuticals ASX:RCE +5.00% 31 Interest Expense is A$-1.30 Mil as of Dec. 2025. GuruFocus rates ASX:RCE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Recce Pharmaceuticals's interest expense for the six months ended in Dec. 2025 was A$ -0.86 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.30 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Recce Pharmaceuticals's Operating Income for the six months ended in Dec. 2025 was A$ -13.75 Mil. Recce Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was A$ -0.86 Mil. Recce Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Recce Pharmaceuticals (ASX:RCE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Recce Pharmaceuticals's Interest Expense for the six months ended in Dec. 2025 was A$-0.86 Mil. Its Operating Income for the six months ended in Dec. 2025 was A$-13.75 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was A$8.96 Mil.

Recce Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Recce Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Recce Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's Interest Expense can be seen below:

Recce Pharmaceuticals Interest Expense Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Interest Expense

Get a 7-Day Free Trial

-0.00

-0.17

-0.81

-1.15

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Interest Expense	Get a 7-Day Free Trial															-0.27	-0.54	-0.71	-0.44	-0.86

31GF Score

Recce Pharmaceuticals Ltd ASX:RCE

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Recce Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.30 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of A$-1.30 Mil mean?

Recce Pharmaceuticals (ASX:RCE) has a Interest Expense of A$-1.30 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Recce Pharmaceuticals and its competitors.

Is Recce Pharmaceuticals' Interest Expense too high?

Recce Pharmaceuticals' current Interest Expense is A$-1.30 Mil. Overall, Recce Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Recce Pharmaceuticals' Interest Expense compare to VRTX and REGN?

Recce Pharmaceuticals' Interest Expense of A$-1.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current Interest Expense is A$-1.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Recce Pharmaceuticals stock overvalued right now?

Recce Pharmaceuticals (ASX:RCE) has a current Interest Expense of A$-1.30 Mil. The current Interest Expense is A$-1.30 Mil. Recce Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current Interest Expense is A$-1.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:DXB ASX:ACW ASX:ATH ASX:ILA ASX:LTP ASX:NYR ASX:PAR ASX:ALA ASX:IMM ASX:ATX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges R9Q:Germany

Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102

Website https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.

31GF Score

Get the complete analysis for ASX:RCE

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42

Price

View ASX:RCE Analysis

See Interest Expense data for all stocks →